Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031

Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031


Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)—Global Forecast to 2031.

The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Additionally, the supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.

However, the high cost of imaging systems restrains the growth of this market. Additionally, the lack of skilled professionals and insufficiencies in the implementation of cancer screening programs pose a significant challenge to the market's growth.

Among the products, in 2024, the IVD segment is expected to account for the largest share of the Europe cancer diagnostics market. IVD instruments provide precise, reliable screening and diagnostic testing through simple workflows and integrated software. Furthermore, IVD consumables assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients. The large market share of this segment is attributed to the advancements in IVD technology, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.

Among the cancer types, in 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The increase in breast cancer cases, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer. Additionally, government initiatives promoting breast cancer awareness regarding diagnosis and treatment boost breast cancer diagnosis. For instance, in October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called ‘Facing Breast Cancer Together’, this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.

Among the end users, in 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increasing cancer cases, the higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.

An in-depth analysis of the Europe cancer diagnostics market provides detailed qualitative and quantitative insights into major countries, namely Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe. In 2023, Germany is estimated to account for the largest share of the Europe cancer diagnostics market. The market growth in Germany is attributed to the increasing prevalence of cancer, the high adoption of advanced technologies, the established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, and initiatives to raise awareness about cancer diagnosis.

Some of the key players operating in the Europe Cancer Diagnostics market report are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).

Scope of the Report:

Europe Cancer Diagnostics Market Size & Trend Analysis—by Product


In Vitro Diagnostics
IVD Consumables
Kits & Assays
Reagents
IVD Instruments
Polymerase Chain Reaction (PCR) Systems
Microarray Readers
Immunoassay Analyzers
Sequencers
Other IVD Instruments
IVD Software & Services

(Other IVD instruments include in-situ hybridization, hematology analyzers, and clinical chemistry analyzers)

Diagnostic Imaging

Imaging Instruments
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Mammography
Ultrasound
Other Imaging Instruments

(Other imaging instruments include Positron Emission Tomography (PET) and X-ray)

Imaging Consumables
Contrast Agents
Syringes and Injectors
Contrast Delivery Systems
Skin Markers
Phantoms
Other Imaging Consumables

(Other imaging consumables include films, gels, transducers, and probes, among others)
Imaging Software and Services

Europe Cancer Diagnostics Market Size & Trend Analysis—by Cancer Type

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Other Cancer Type

Note: Other cancer types include leukemia, lymphoma, stomach, ovarian, melanoma, kidney, and cervical cancers.

Europe Cancer Diagnostics Market Size & Trend Analysis—by End User

Hospital & Diagnostics Laboratories
Diagnostic Imaging Centers
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes

Europe Cancer Diagnostics Market Size & Trend Analysis—by Country

Germany
France
Italy
U.K.
Spain
Switzerland
Netherlands
Rest of Europe

Europe Cancer Diagnostics Market - Report Summary
Report MetricsDetails
Years Considered2022 - 2031
Base Year2023
Forecast Period2024-2031
Page Count209
Units ReferencedValue (USD Million)
Segments/Key TopicsMarket by Product, Cancer Type, End User, and Geography
Regions CoveredEurope (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe)
Key Companies MentionedF. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic Inc. (U.S).


FAQs About the Report

What is the focus of the Europe cancer diagnostics market?


The Europe cancer diagnostics market covers the market sizes & forecasts of offering, including product, cancer type, and end user. The Europe cancer diagnostics market studied in this report involves the value analysis of various segments and sub-segments of the Europe cancer diagnostics market at country levels.

What is the value of revenue generated from sales of cancer diagnostic products in Europe? At what rate is their demand expected to grow for the next 5-7 years?

The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% during the forecast period.

Which Product segment held the major share of the market in 2024?

In 2024, the In Vitro Diagnostics segment is expected to account for the largest share of the Europe cancer diagnostics market.

Which Cancer Type segment is projected to create more traction in the Europe cancer diagnostics market?

The breast cancer segment is projected to create more traction in the Europe cancer diagnostics market.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the Europe cancer diagnostics market?

The Europe cancer diagnostics market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Furthermore, supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.

Who are the major players operating in the Europe cancer diagnostics market?

The key players operating in the Europe cancer diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic Inc. (U.S).

Which countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

France, Germany, and the U.K. are projected to offer significant growth opportunities for the vendors in this market due to factors such as increasing cancer incidence, supporting government initiatives, rising healthcare expenditure, growing demand for precision oncology, and growing R&D investments for cancer.


1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Rising Cancer Prevalence Coupled with Technological Advancements Fueling the Market Growth
4.2.1.2. Supporting Initiatives for Early Cancer Diagnosis and Creating Awareness Driving the Market Growth
4.2.1.3. Growing Adoption and Supporting Initiatives for Precision Cancer Diagnostics Creating Opportunities for the Market Players
4.2.1.4. Insufficiencies in the Implementation of Cancer Screening Programs: A Challenge for Cancer Diagnosis in Europe
4.2.2. Factor Analysis
4.3. Trends
4.4. Regulatory Analysis
4.4.1. Regulatory Analysis for IVD Technologies
4.4.2. Regulatory Analysis for Diagnostic Imaging Devices
4.5. Porter’s Five Forces Analysis: Diagnostic Imaging Technologies for Cancer Screening
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Porter’s Five Forces Analysis: IVD Technologies for Cancer Screening
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
4.7. Pricing Analysis
5. Europe Cancer Diagnostics Market–by Product
5.1. Overview
5.2. In Vitro Diagnostics
5.2.1. IVD Consumables
5.2.1.1. Kits & Assays
5.2.1.2. Reagents
5.2.2. IVD Instruments
5.2.2.1. Sequencers
5.2.2.2. Polymerase Chain Reaction (PCR) Systems
5.2.2.3. Immunoassay Analyzers
5.2.2.4. Microarray Readers
5.2.2.5. Other IVD Instruments
5.2.3. IVD Software & Services
5.3. Diagnostic Imaging
5.3.1. Imaging Instruments
5.3.1.1. Computed Tomography (CT)
5.3.1.2. Mammography
5.3.1.3. Magnetic Resonance Imaging (MRI)
5.3.1.4. Ultrasound
5.3.1.5. Other Imaging Instruments
5.3.2. Imaging Consumables
5.3.2.1. Contrast Agents
5.3.2.2. Syringes & Injectors
5.3.2.3. Contrast Delivery Systems
5.3.2.4. Skin Markers
5.3.2.5. Phantoms
5.3.2.6. Other Imaging Consumables
5.3.3. Imaging Software & Services
6. Europe Cancer Diagnostics Market–by Cancer Type
6.1. Overview
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Other Cancer Types
7. Europe Cancer Diagnostics Market–by End User
7.1. Overview
7.2. Hospitals & Diagnostic Laboratories
7.3. Diagnostic Imaging Centers
7.4. Pharmaceutical & Biotechnology Companies
7.5. Academic & Research Institutes
8. Europe Cancer Diagnostics Market Assessment— by Geography
8.1. Overview
8.2. Germany
8.3. France
8.4. U.K.
8.5. Italy
8.6. Spain
8.7. Switzerland
8.8. Netherlands
8.9. Rest of Europe (RoE)
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2023)
9.4.1. Europe Cancer IVD Market Share Analysis (2023)
9.4.1.1. F. Hoffmann-La Roche Ltd (Switzerland)
9.4.1.2. Thermo Fisher Scientific Inc. (U.S.)
9.4.1.3. Illumina, Inc. (U.S.)
9.4.2. Europe Diagnostic Imaging Market Share Analysis (2023)
9.4.2.1. GE Healthcare Technologies Inc. (U.S.)
9.4.2.2. Siemens Healthineers AG (Germany)
9.4.2.3. Hologic, Inc. (U.S.)
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, SWOT Analysis)
10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. QIAGEN N.V.
10.4. Abbott Laboratories
10.5. Illumina, Inc.
10.6. Siemens Healthineers AG
10.7. GE Healthcare Technologies Inc.
10.8. Hologic, Inc.
10.9. Koninklijke Philips N.V.
10.10. Fujifilm Holdings Corporation
10.11. Canon Medical Systems Corporation
(Note: SWOT Analysis of the Top 6 Companies Will Be Provided)
11. Appendix
11.1. Related Reports
Table 1 Europe: Single and Multi Biomarker Test Availability by Country, 2021
Table 2 Average Selling Prices: IVD Instruments
Table 3 Average Selling Prices: Diagnostic Imaging Instruments
Table 4 Europe Cancer Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 5 Europe Cancer In Vitro Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 6 Europe Cancer In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Europe Cancer IVD Consumables Market, by Type, 2022–2031 (USD Million)
Table 8 Europe Cancer IVD Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 9 IVD Kits & Assays Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 10 IVD Reagents Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 11 Europe Cancer IVD Instruments Market, by Type, 2022–2031 (USD Million)
Table 12 Europe Cancer IVD Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Sequencers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 14 Polymerase Chain Reaction (PCR) Systems Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 15 Immunoassay Analyzers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 16 Microarray Readers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 17 Other IVD Instruments Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 18 Europe Cancer IVD Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Europe Imaging-Based Cancer Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 20 Europe Imaging-Based Cancer Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Europe Cancer Diagnostic Imaging Instruments Market, by Type, 2022–2031 (USD Million)
Table 22 Europe Cancer Diagnostic Imaging Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Computed Tomography (CT) Scanners per 1,000,000 Inhabitants in European Countries (2021)
Table 24 CT Scanners Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 25 Mammography Machines per 1,000,000 Inhabitants in European Countries (2021)
Table 26 Mammography Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 27 Magnetic Resonance Imaging (MRI) Units per 1,000,000 Inhabitants in European Countries (2021)
Table 28 MRI Scanners Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 29 Ultrasound Scanners Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 30 Other Imaging Instruments Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 31 Europe Cancer Diagnostic Imaging Consumables Market, by Type, 2022–2031 (USD Million)
Table 32 Europe Cancer Diagnostic Imaging Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 33 Contrast Agents Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 34 Syringes & Injectors Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 35 Contrast Delivery Systems Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 36 Skin Markers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 37 Phantoms Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 38 Other Imaging Consumables Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 39 Europe Cancer Diagnostic Imaging Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 40 Europe Cancer Diagnostics Market, by Cancer Type, 2022–2031 (USD Million)
Table 41 Number of New Breast Cancer Cases in European Countries, 2022–2030
Table 42 Europe Cancer Diagnostics Market for Breast Cancer, by Country/Region, 2022–2031 (USD Million)
Table 43 Europe Cancer Diagnostics Market for Lung Cancer, by Country/Region, 2022–2031 (USD Million)
Table 44 Europe Cancer Diagnostics Market for Colorectal Cancer, by Country/Region, 2022–2031 (USD Million)
Table 45 Number Of New Prostate Cancer Cases In European Countries, 2022–2030
Table 46 Europe Cancer Diagnostics Market for Prostate Cancer, by Country/Region, 2022–2031 (USD Million)
Table 47 Number of Other Cancer Cases in European Countries, 2022–2030
Table 48 Europe Cancer Diagnostics Market for Other Cancer Types, by Country/Region, 2022–2031 (USD Million)
Table 49 Europe Cancer Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 50 Number of Hospitals in European Countries, 2021
Table 51 Europe Cancer Diagnostics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 52 Europe Cancer Diagnostics Market for Diagnostic Imaging Centers, by Country/Region, 2022–2031 (USD Million)
Table 53 Europe Cancer Diagnostics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 54 Europe Cancer Diagnostics Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 55 Europe: Cancer Diagnostics Market, by Country/Region, 2022—2031 (USD Million)
Table 56 Germany: Key Macro & Micro Indicators
Table 57 Germany: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 58 Germany: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 59 Germany: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 60 Germany: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 61 Germany: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 62 Germany: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 63 Germany: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 64 Germany: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 65 Germany: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 66 France: Healthcare Expenditure, 2017–2020 (USD Million)
Table 67 France: Key Macro & Micro Indicators
Table 68 France: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 69 France: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 70 France: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 71 France: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 72 France: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 73 France: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 74 France: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 75 France: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 76 France: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 77 U.K.: Key Macro & Micro Indicators
Table 78 U.K.: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 79 U.K.: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 80 U.K: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 81 U.K: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 82 U.K.: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 83 U.K.: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 84 U.K.: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 85 U.K.: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 86 U.K.: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 87 Italy: Key Macro & Micro Indicators
Table 88 Italy: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 89 Italy: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 90 Italy: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 91 Italy: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 92 Italy: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031(USD Million)
Table 93 Italy: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 94 Italy: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 95 Italy: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 96 Italy: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 97 Spain: Key Macro & Micro Indicators
Table 98 Spain: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 99 Spain: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 100 Spain: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 101 Spain: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 102 Spain: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 103 Spain: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 104 Spain: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 105 Spain: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 106 Spain: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 107 Switzerland: Key Macro & Micro Indicators
Table 108 Switzerland: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 109 Switzerland: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 110 Switzerland: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 111 Switzerland: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 112 Switzerland: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 113 Switzerland: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 114 Switzerland: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 115 Switzerland: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 116 Switzerland: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 117 Netherlands: Key Macro & Micro Indicators
Table 118 Netherlands: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 119 Netherlands: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 120 Netherlands: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 121 Netherlands: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 122 Netherlands: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 123 Netherlands: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 124 Netherlands: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 125 Netherlands: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 126 Netherlands: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 127 Rest Of Europe: Number Of New Cancer Cases, by Country, 2022 Vs. 2030
Table 128 Rest Of Europe: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 129 Rest Of Europe: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 130 Rest Of Europe: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 131 Rest Of Europe: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 132 Rest Of Europe: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 133 Rest Of Europe: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 134 Rest Of Europe: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 135 Rest Of Europe: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 136 Rest Of Europe: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 137 Recent Developments, by Company, 2020-2024
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown Of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth for ecast Approach
Figure 7 Europe Cancer Diagnostics Market, by Product, 2024 VS. 2031 (USD Million)
Figure 8 Europe Cancer Diagnostics Market, by Cancer Type, 2024 VS. 2031 (USD Million)
Figure 9 Europe Cancer Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 10 Europe Cancer Diagnostics Market, by Country/Region
Figure 11 Impact Analysis of Market Dynamics
Figure 12 Europe: Estimated Number of New Cancer Cases 2020 VS. 2035
Figure 13 Eu Regulatory Pathway - IVDR 2017/746
Figure 14 Porter’s Five forces Analysis
Figure 15 Porter’s Five forces Analysis
Figure 16 Europe Cancer Diagnostics Market, by Product, 2024 VS. 2031 (USD Million)
Figure 17 Europe Cancer Diagnostics Market, by Cancer Type, 2024 VS. 2031 (USD Million)
Figure 18 Number of New Lung Cancer Cases in European Countries, 2022–2030
Figure 19 Number of New Colon Cancer Cases in European Countries, 2022–2030
Figure 20 Number of New Rectal Cancer Cases in European Countries, 2022–2030
Figure 21 Europe Cancer Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 22 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 23 Number of Cancer Cases in European Countries, 2022
Figure 24 Europe Cancer Diagnostics Market, by Country, 2024 Vs. 2031 (USD Million)
Figure 25 Europe Cancer Diagnostics Market: Regional Snapshot
Figure 26 Germany: Number of New Cancer Cases, 2022—2040
Figure 27 France: Number of New Cancer Cases, 2022—2040
Figure 28 U.K.: Number of New Cancer Cases, 2022—2040
Figure 29 Italy: Number of New Cancer Cases, 2022—2040
Figure 30 Italy: Number of Biotechnolgy Firms, 2010—2021
Figure 31 Spain: Healthcare Expenditure, 2017–2021 (USD Million)
Figure 32 Spain: Number of New Cancer Cases, 2022—2040
Figure 33 Switzerland: Number of New Cancer Cases, 2022—2040
Figure 34 Switzerland: Healthcare Expenditure, 2020–2024 (USD)
Figure 35 Netherlands: Number of New Cancer Cases, 2022—2040
Figure 36 Healthcare Expenditures In Belgium, Greece, Austria, and Poland, 2018-2021 (USD Million)
Figure 37 Key Growth Strategies Adopted by Leading Players, 2020– 2024
Figure 38 Europe Cancer In Vitro Diagnostics (IVD) Market: Competitive Benchmarking
Figure 39 Europe Cancer Diagnostic Imaging Market: Competitive Benchmarking
Figure 40 Europe Cancer In Vitro Diagnostics Market Share Analysis, by Key Players, 2023 (%)
Figure 41 Europe Cancer Diagnostics Market Share Analysis for Imaging, by Key Players, 2023 (%)
Figure 42 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2022)
Figure 43 Thermo Fisher Scientific Inc.: Financial Snapshot (2022)
Figure 44 QIAGEN N.V.: Financial Snapshot (2022)
Figure 45 Abbott Laboratories: Financial Snapshot (2022)
Figure 46 Illumina, Inc.: Financial Snapshot (2022)
Figure 47 Siemens Healthineers AG: Financial Snapshot (2023)
Figure 48 GE Healthcare Technologies Inc.: Financial Snapshot (2022)
Figure 49 Hologic, Inc.: Financial Snapshot (2023)
Figure 50 Koninklijke Philips N.V.: Financial Snapshot (2022)
Figure 51 Fujifilm Holdings Corporation: Financial Snapshot (2022)
Figure 52 Canon Medical Systems Corporation (A Subsidiary Of Canon Inc.): Financial Snapshot (2022)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings